Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

TheManUpstairs Jun. 17 at 11:25 AM

Silver-lining: replenishing the equity incentive pool helps conserve cash. With $IMNN focused on reaching the milestones needed for the second bridge tranche, paying a portion of compensation in equity rather than cash actually strengthens the runway. BTW: One thing worth keeping in mind. The latest management option grants (Aug 2025) carry a $9.20 exercise price. With the stock trading around $2, those options are currently deeply underwaterout, out-of-the-money, and essentially worthless unless the share price recovers significantly

0 · Reply

ConcernedCitizen23 Jun. 17 at 11:12 AM

$IMNN since the company has presented all of its big data already I wonder why the CEO is going to more scientific meetings?!? Can you say shopping for partners?!? Let’s wish her luck

0 · Reply

ConcernedCitizen23 Jun. 17 at 11:03 AM

$IMNN good volume and red to green in premarket $MRNA $LLY $PFE

0 · Reply

bomber1 Jun. 17 at 10:30 AM

$IMNN the employees who are receiving their compensation in shares are continuously losing money as the stock continues to fall every day forever; It's likely that soon they will all resign, because they are practically working for free

0 · Reply

ConcernedCitizen23 Jun. 16 at 10:53 PM

$IMNN here’s the reality, they already gave out almost all the shares from the 2018 plan and they will do 1,000,000 shares in the future over time. Fine with me. It’s not tomorrow and could take 8 years to give out like the 2018 plan

0 · Reply

focafoca99 Jun. 16 at 9:45 PM

$IMNN amended its 2018 Stock Incentive Plan, adding 1,000,000 shares to the pool. https://www.rapidticker.com/news/imnn-sec-filing-e17ade

0 · Reply

ConcernedCitizen23 Jun. 16 at 6:56 PM

$IMNN this stock price has no basis in reality. I’m holding until we get to a real valuation of a phase 3 company in the $200-500 million range

1 · Reply

AZOZ Jun. 16 at 5:03 PM

$IMNN Oversold swing idea 💡

1 · Reply

TheRealShortSqueezy Jun. 16 at 1:41 PM

🚨 $CUE Strengthening Leadership for the Next Phase Cue Biopharma is entering a new phase of growth after announcing a major board transition and the addition of two experienced biotech leaders to its Board of Directors. ✅ Daniel Camardo has helped lead multiple commercial launches and blockbuster therapies throughout his biotech career ✅ Viola Meehan brings more than 30 years of financial leadership experience across biotechnology companies ✅ The board refresh follows several leadership changes made throughout 2026 as CUE positions for future growth Beyond the leadership changes, Cue remains focused on advancing CUE-401 and expanding its autoimmune disease strategy while pursuing additional partnership and licensing opportunities. Communicated Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $IMNN $IOVA $HOOK.X $ACHV

1 · Reply

bxp2390 Jun. 15 at 2:05 PM

$IMNN Imunon's Phase 2 was published in one of the most prestigious journals in their discipline and is already being cited a lot. These articles are peer reviewed by experts before they can make it into such journals (as some of you may know). Failed trials or bad protocols don't get published. You can take a look yourselves, the issue is open-access so paper is downloadable. https://www.gynecologiconcology-online.net/article/S0090-8258(25)00797-8/fulltext

1 · Reply

IMUNON Announces Up to $10 Million Cash Financing

2026-05-12T16:03:21.000Z - 5 weeks ago

Imunon reports Q1 EPS (84c), consensus ($1.28)

May 12, 2026, 11:00 AM EDT - 5 weeks ago

Imunon Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 5 weeks ago

Imunon Earnings release: Q1 2026

May 12, 2026, 11:00 AM EDT - 5 weeks ago

Imunon Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 5 weeks ago

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 8:30 AM EDT - 6 weeks ago

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

May 4, 2026, 8:00 AM EDT - 6 weeks ago

Imunon Proxy statement: Proxy filing

2026-04-17T12:46:27.000Z - 2 months ago

Imunon initiated with a Buy at Maxim

Mar 31, 2026, 11:00 AM EDT - 2 months ago

Imunon Earnings Call Transcript: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 2 months ago

Imunon Annual report: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 2 months ago

Imunon Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 2 months ago

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

2026-03-25T12:35:38.000Z - 3 months ago

Imunon announces final clinical data from OVATION 2 clinical trial

Mar 25, 2026, 8:05 AM EDT - 3 months ago

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

Mar 24, 2026, 8:00 AM EDT - 3 months ago

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

2026-02-05T13:21:18.000Z - 4 months ago

Imunon announces reorganization to eliminate headcount for Phase 3 trial

Feb 5, 2026, 8:05 AM EST - 4 months ago

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

2025-12-30T13:50:29.000Z - 6 months ago

Imunon prices 1.94M shares at $3.61 in registered direct offering

Dec 30, 2025, 8:30 AM EST - 6 months ago

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

2025-12-29T16:15:14.000Z - 6 months ago

Imunon CEO says ‘poised for key milestones’ as company enters 2026

Dec 29, 2025, 11:10 AM EST - 6 months ago

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Nov 13, 2025, 11:00 AM EST - 7 months ago

Imunon Earnings Call Transcript: Q3 2025

Nov 13, 2025, 11:00 AM EST - 7 months ago

Imunon Quarterly report: Q3 2025

Nov 13, 2025, 11:00 AM EST - 7 months ago

Imunon Earnings release: Q3 2025

2025-11-13T12:50:55.000Z - 7 months ago

Imunon reports Q3 EPS ($1.16) vs ($3.76) last year

2025-11-13T12:50:47.000Z - 7 months ago

Imunon expects cash to fund operations into Q1 of 2026

Nov 13, 2025, 7:45 AM EST - 7 months ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 1:30 PM EST - 7 months ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

2025-11-10T13:00:28.000Z - 7 months ago

Imunon showcases progress on IMNN-001 at R&D Day

Nov 10, 2025, 7:30 AM EST - 7 months ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 7 months ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 7 months ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 8 months ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

2025-10-30T12:21:17.000Z - 8 months ago

Imunon to present Phase 3 OVATION 3 study of IMNN-001

Oct 30, 2025, 8:00 AM EDT - 8 months ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 8 months ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 8 months ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 8 months ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

2025-10-14T12:36:43.000Z - 8 months ago

Imunon to present Phase 3 OVATION trial of IMNN-001

Oct 14, 2025, 8:20 AM EDT - 8 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

2025-09-22T12:20:43.000Z - 9 months ago

Imunon: OVATION 2 study results reinforce IMNN-001 efficacy benefits

Sep 22, 2025, 8:05 AM EDT - 9 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

2025-09-19T12:10:26.000Z - 9 months ago

Imunon to present translational data from Phase 2 OVATION 2 Study of IMNN-001

Sep 19, 2025, 8:05 AM EDT - 9 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

2025-08-28T12:15:21.000Z - 10 months ago

Imunon regains compliance with Nasdaq min bid price listing requirement

Aug 28, 2025, 8:05 AM EDT - 10 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 11 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 11:00 AM EDT - 11 months ago

Imunon Earnings Call Transcript: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 11 months ago

Imunon Quarterly report: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 11 months ago

Imunon Earnings release: Q2 2025

2025-08-05T12:16:44.000Z - 11 months ago

Imunon sees cash runway into 4Q25

2025-08-05T12:10:16.000Z - 11 months ago

Imunon reports Q2 EPS ($2.15), consensus ($4.99)

Aug 5, 2025, 8:00 AM EDT - 11 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-07-30T12:10:34.000Z - 11 months ago

Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001

Jul 30, 2025, 8:05 AM EDT - 11 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 11 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

2025-07-28T12:20:54.000Z - 11 months ago

Imunon board approves 15% stock dividend

Jul 28, 2025, 8:05 AM EDT - 11 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

2025-07-23T12:15:59.000Z - 11 months ago

Imunon announces 1-for-15 reverse split ratio

Jul 23, 2025, 8:00 AM EDT - 11 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 1 year ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 1 year ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 12, 2025, 11:30 AM EDT - 1 year ago

Imunon Transcript: Life Sciences Investor Forum

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Imunon Proxy statement: Proxy Filing

Jun 3, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 1 year ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 30, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Imunon Proxy statement: Proxy Filing

May 27, 2025, 8:05 AM EDT - 1 year ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 1 year ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 1 year ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 19, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

May 15, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 13, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings Call Transcript: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Quarterly report: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 1 year ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 1 year ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings Call Transcript: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Annual report: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings release: Q4 2024

Feb 27, 2025, 8:05 AM EST - 1 year ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 1 year ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.

TheManUpstairs Jun. 17 at 11:25 AM

0 · Reply

ConcernedCitizen23 Jun. 17 at 11:12 AM

$IMNN since the company has presented all of its big data already I wonder why the CEO is going to more scientific meetings?!? Can you say shopping for partners?!? Let’s wish her luck

0 · Reply

ConcernedCitizen23 Jun. 17 at 11:03 AM

$IMNN good volume and red to green in premarket $MRNA $LLY $PFE

0 · Reply

bomber1 Jun. 17 at 10:30 AM

0 · Reply

ConcernedCitizen23 Jun. 16 at 10:53 PM

0 · Reply

focafoca99 Jun. 16 at 9:45 PM

$IMNN amended its 2018 Stock Incentive Plan, adding 1,000,000 shares to the pool. https://www.rapidticker.com/news/imnn-sec-filing-e17ade

0 · Reply

ConcernedCitizen23 Jun. 16 at 6:56 PM

$IMNN this stock price has no basis in reality. I’m holding until we get to a real valuation of a phase 3 company in the $200-500 million range

1 · Reply

AZOZ Jun. 16 at 5:03 PM

$IMNN Oversold swing idea 💡

1 · Reply

TheRealShortSqueezy Jun. 16 at 1:41 PM

1 · Reply

bxp2390 Jun. 15 at 2:05 PM

1 · Reply

ConcernedCitizen23 Jun. 15 at 1:09 PM

$IMNN there’s money in the bank, at least 7 phase 3 clinical sites and prestige phase 2 closing enrollment like ready for news drop. I’m pretty optimistic here.

0 · Reply

jjegglie Jun. 13 at 8:27 PM

$IMNN 1. Don't be a coward. If you have something to say, @ me. 2. I post under my own name. Unlike you. Do you even know what anonymous means? 3. I notice you didn't make any effort to refute my factual statements. Attack the messenger since you can't attack the message, right? 4. But to entertain your delusions, I am the one who is actually founded in scientific reality here. The phase 2 results were statistically insignificant and the trial oversampled responders. I didn't make that up, Sleazy Statborg said it herself.

0 · Reply

BA777 Jun. 13 at 4:31 PM

$IMNN

2 · Reply

bxp2390 Jun. 11 at 3:03 PM

$IMNN Anonymous blogger knows more than the scientific community I'm sure. Their Phase 2 was published in Gynecologic Oncology, one of the best journals in this discipline and is already cited quite a bit. But what do those silly scientists and researchers spending a lifetime doing this know?

1 · Reply

jjegglie Jun. 10 at 5:29 PM

$IMNN This has to be satire. Right? The only thing P2 accomplished is to clearly demonstrate how this garbage will fail P3. Statistically insignificant and oversampled responders. The market is clearly demonstrating that it, too, understands these truths. Next, the "unique" financing. 7 months of cash from (curiously unnamed) donors. First, it wasn't non dilutive. Just the interest on the notes alone will require 5% dilution to cover. Let alone the 100% dilution required to pay them back. The astounding part is low information longs cheering this. Celsion just subordinated common shareholders behind preferred equity and debt holders to the tune of 125% of market cap. Congratulations, you've been completely rugged and your shared are now less than worthless. All to keep Sleazy Statborg, Johnny Lurch, Mikey Turd-ugno and the rest of these criminal grifters 6/7 figure salaries paid. Now they can dilute common shareholders at will. This is liklier 5 cents than $5 EOY

0 · Reply

RaKa82 Jun. 10 at 2:37 PM

$IMNN hmm short interest dropped by 61%. Maybe they know something we don’t know 🤔

0 · Reply

bxp2390 Jun. 10 at 11:57 AM

$IMNN Last year same time IMNN stock crossed $100 million in market capitalization on P2 results. Since then P2 result update have shown even better prospects. But P2s are never designed to be proofs of actual outcomes, that is the goal of P3 trials. Over the last year Imunon's P3 trials have started and grown at a faster rate than expected. The most recent financing was innovative for a small cap biotech in how little dilution it brought. With all of this the market cap is now down to 10% of what it was a year ago, now around $9 million - for the value of the entire company to a buyer today if they wanted. Next catalyst is probably some sort of a P3 trial update, maybe enrollment/sites. But don't see this hang here so low for too long. Predicting $5+ by end of summer or maybe more.

1 · Reply

jjegglie Jun. 9 at 7:21 PM

$IMNN New all time low. Down 99.9999989% from all time high. So so close to adding that 6th 9. Still no products. Still no prospects. Still criminally corrupt management. Target price: Still and forever $0

0 · Reply

I_AM_GROOT Jun. 9 at 2:09 AM

$IMNN closer to $1.00 one more RS this time next yr?

1 · Reply

TheManUpstairs Jun. 5 at 5:22 PM

$IMNN The long-term follow-up from the Phase 2 OVATION 2 trial is the ultimate catalyst for the current Phase 3. As the 36 and 48-month survival data matures, it gives principal investigators like Dr. Thaker undeniable proof to present to the oncology community. Hard, long-term survival evidence is the best marketing tool to rapidly activate more clinical sites and accelerate enrollment for OVATION 3. Every positive follow-up update directly de-risks Phase 3 and forces Big Pharma to pay a higher premium for the M&A buyout. I mean, the machine is rolling. ٩(◕‿◕｡)۶

0 · Reply

TheManUpstairs Jun. 5 at 5:05 PM

This financing gives $IMNN the runway to execute on what management has been talking about for months: accelerating enrollment in OVATION-3, with a target of reaching 80 patients by year-end. What I’ll be watching over the next several months: • OVATION-3 enrollment updates and site expansion • Additional long-term follow-up from OVATION-2, where the survival data have already been highly unusual for this indication • Progress in the HRD+ population, which management has repeatedly highlighted as the subgroup with the strongest potential signal • Any further discussion around the interim analyses and the possibility of an earlier regulatory pathway

0 · Reply

TheManUpstairs Jun. 5 at 4:49 PM

$IMNN We now have a rather unusual bridge financing for a development-stage biotech. No warrants, no convertible preferred stock, no immediate common-share dilution. Even Zacks highlighted the structure as being more shareholder-friendly than many alternative biotech financings and maintained its $25/share valuation after reviewing the deal. For a company currently trading at just $2.08, this provides a pretty solid initial valuation to start with. 🧃

0 · Reply

Market Cap	8.19M
Revenue (ttm)	0.00
Net Income (ttm)	-14.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	57,500
Avg Vol	44,848
Day's Range	N/A - N/A
Shares Out	4.20M
Stochastic %K	6%
Beta	1.95
Analysts	Strong Sell
Price Target	$17.00